Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of SHR7280 Dry Suspension vs Tablets
NCT05868057Phase 1Completed
- Sponsor
- Hengrui
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SHR7280 in endometriosis, Uterine Fibroids (UF), prostate cancer (PCa) and 1 more (2 arms), sponsored by Hengrui. Primary endpoints: Area Under the Curve from time 0 to t, Area Under the Curve from time 0 to infinity and 2 more. Started May 2023; status: completed.
02
Drugs
SHR7280
03
Conditions
endometriosisUterine Fibroids (UF)prostate cancer (PCa)assisted reproductive technology (ART)
Beyond the preview
Go deeper on NCT05868057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868057.